Strand Therapeutics picks up $52m Series A
Strand Therapeutics, a developer of next-generation, programmable mRNA therapeutics for cancer immunotherapy and other diseases, has raised $52 million in Series A financing.
Strand Therapeutics, a developer of next-generation, programmable mRNA therapeutics for cancer immunotherapy and other diseases, has raised $52 million in Series A financing.